title: Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure.
abstract: Intact parathyroid hormone (iPTH) radioimmunoassay represents an important advancement in the measurement of serum PTH levels, permitting the evaluation of the actual rate of secretion of the parathyroid glands. The aim of the study was to compare the value of intact and C-terminal PTH measurements in predicting the osteodystrophic bone lesion in predialysis patients with chronic renal failure (CRF). We have studied 37 subjects with CRF who were receiving conservative treatment. In each subject a transiliac bone biopsy for histomorphometric examination was performed in addition to the assay of serum intact and C-terminal PTH, osteocalcin, and alkaline phosphatase. Serum C-terminal and intact PTH levels were closely correlated, both showing a high degree of correlation with serum osteocalcin. Similar degrees of correlation were observed between the two PTH assays and the histologic parameters osteoblastic surface (ObS/BS) and osteoclastic surface (OcS/BS). The evaluation of specificity and sensitivity of the two PTH assays in selecting patients with normal or pathologic histomorphometric parameters gave an equivalent number of false positive and negative cases. Based on discriminant analysis of histomorphometric parameters, intact PTH shows a higher discriminant power when compared with C-terminal PTH assay for the parameters OcS/BS and eroded surface (ES/BS), but without practical clinical value. In conclusion, in analogy to the short lived N-terminal PTH fragment assay, prediction of elementary hyperparathyroid bone lesions in predialysis CRF is not improved by the use of intact PTH as compared to the more traditional C-terminal assay.
authors.affiliation: Chair of Nephrology, La Sapienza University, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Coen
authors.forename: S
authors.initials: S
authors.lastname: Mazzaferro
authors.forename: P
authors.initials: P
authors.lastname: Ballanti
authors.forename: E
authors.initials: E
authors.lastname: Bonucci
authors.forename: G A
authors.initials: GA
authors.lastname: Cinotti
authors.forename: G
authors.initials: G
authors.lastname: Fondi
authors.forename: M
authors.initials: M
authors.lastname: Manni
authors.forename: M
authors.initials: M
authors.lastname: Pasquali
authors.forename: I
authors.initials: I
authors.lastname: Perruzza
authors.forename: D
authors.initials: D
authors.lastname: Sardella
mesh_terms: D000328:Adult; D000368:Aged; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis; D015592:Immunoradiometric Assay; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D010446:Peptide Fragments / Q000032:analysis
chemical_list: D010281:Parathyroid Hormone; D010446:Peptide Fragments